Trxade Group (MEDS) Stock Price

Trxade Group Price

NYSE·CLOSED
3.45USD+0.37 (+11.33 %)
Market closed

Over the last 11 years Trxade Group grew revenue by 23.6% annually, reaching 8.27 M USD. For Trxade Group, the net margin of -215.7% is down versus -5.5% a few years ago. The consensus 12-month price target for Trxade Group is 6.89 USD, about 99.6% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 30% above its 52-week low.

Trxade Group stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Trxade Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Trxade Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Trxade Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Trxade Group Stock Price History
DateTrxade Group Price
8/5/20263.45 USD
8/4/20263.08 USD
8/3/20263.24 USD
7/31/20263.02 USD
7/30/20263.16 USD
7/29/20263.20 USD
7/27/20263.04 USD
7/24/20263.28 USD
7/23/20263.58 USD
7/22/20263.58 USD
7/21/20263.52 USD
7/20/20262.71 USD
7/17/20262.65 USD
7/16/20262.66 USD
7/15/20262.84 USD
7/14/20262.93 USD
7/13/20262.91 USD
7/10/20263.07 USD
7/9/20262.95 USD
7/8/20262.88 USD
7/7/20262.98 USD
7/6/20263.13 USD
7/2/20262.98 USD
7/1/20263.07 USD
6/30/20263.10 USD
6/29/20262.93 USD
6/26/20263.05 USD
6/25/20262.86 USD
6/24/20262.82 USD
6/23/20263.12 USD
6/22/20263.10 USD
6/18/20263.39 USD
6/17/20263.70 USD
6/16/20263.69 USD
6/15/20263.74 USD
6/12/20263.48 USD
6/11/20263.72 USD
6/10/20263.74 USD
6/9/20263.63 USD
6/8/20264.02 USD
6/5/20264.35 USD
6/4/20264.29 USD
6/3/20264.39 USD
6/2/20264.25 USD
6/1/20263.85 USD
5/29/20263.42 USD
5/28/20263.72 USD
5/27/20263.16 USD
5/26/20263.82 USD
5/22/20264.15 USD
5/21/20265.35 USD
5/20/20266.45 USD
5/19/20268.40 USD
5/18/20268.70 USD
5/15/20264.20 USD
5/14/20264.70 USD
5/13/20264.85 USD
5/12/20263.95 USD
5/11/20264.60 USD
5/8/20264.20 USD
5/7/20264.40 USD
5/6/20264.65 USD
5/5/20265.15 USD
5/4/20265.20 USD
5/1/20265.40 USD
4/30/20265.50 USD
4/29/20265.40 USD
4/28/20265.75 USD
4/27/20266.25 USD
4/24/20266.50 USD
4/23/20266.80 USD
4/22/20267.05 USD
4/21/20266.70 USD
4/20/20266.60 USD
4/17/20267.20 USD
4/16/20267.35 USD
4/15/20267.40 USD
4/14/20267.20 USD
4/13/20266.00 USD
4/10/20266.00 USD
4/9/20265.30 USD
4/8/20266.30 USD
4/7/20266.35 USD
4/6/20265.15 USD
4/2/20265.10 USD
4/1/20265.35 USD
3/31/20264.80 USD
3/30/20265.00 USD
3/27/20265.05 USD
3/26/20265.55 USD
3/25/20266.25 USD
3/24/20265.80 USD
3/23/20266.30 USD
3/20/20266.85 USD
3/19/20266.00 USD
3/18/20266.70 USD
3/17/20267.80 USD
3/16/20268.30 USD
3/13/20268.15 USD
3/12/20268.30 USD
3/11/20269.60 USD
3/10/20269.10 USD
3/9/20268.75 USD
3/6/20268.25 USD
3/5/20269.65 USD
3/4/202610.65 USD
3/3/202610.95 USD
3/2/202611.65 USD
2/27/202611.95 USD
2/26/202611.75 USD
2/25/202612.10 USD
2/24/202612.15 USD
2/23/202612.50 USD
2/20/202611.40 USD
2/19/202612.80 USD
2/18/202612.90 USD
2/17/202612.90 USD
2/13/202613.95 USD
2/12/202614.05 USD
2/11/202615.70 USD
2/10/202615.10 USD
2/9/202615.35 USD
2/6/202615.60 USD
2/5/202615.95 USD
2/4/202616.75 USD
2/3/202618.10 USD
2/2/202616.70 USD
1/30/202617.95 USD
1/29/202616.75 USD
1/28/202618.85 USD
1/27/202619.65 USD
1/26/202619.25 USD
1/23/202620.10 USD
1/22/202620.35 USD
1/21/202619.85 USD
1/20/202619.50 USD
1/16/202620.30 USD
1/15/202620.40 USD
1/14/202620.90 USD
1/13/202621.00 USD
1/12/202621.70 USD
1/9/202619.65 USD
1/8/202620.15 USD
1/7/202620.25 USD
1/6/202621.00 USD
1/5/202620.75 USD
1/2/202621.70 USD
12/31/202520.00 USD
12/30/202518.40 USD
12/29/202519.00 USD
12/26/202520.25 USD
12/24/202521.70 USD
12/23/202521.40 USD
12/22/202523.35 USD
12/19/202524.30 USD
12/18/202523.95 USD
12/17/202525.10 USD
12/16/202527.00 USD
12/15/202529.00 USD
12/12/202528.65 USD
12/11/202531.00 USD
12/10/202530.60 USD
12/9/202530.10 USD
12/8/202530.50 USD
12/5/202528.35 USD
12/4/202530.50 USD
12/3/202528.40 USD
12/2/202528.00 USD
12/1/202527.95 USD
11/28/202530.00 USD
11/26/202531.60 USD
11/25/202527.50 USD
11/24/202525.55 USD
11/21/202525.00 USD
11/20/202524.45 USD
11/19/202528.95 USD
11/18/202528.65 USD
11/17/202529.25 USD
11/14/202532.30 USD
11/13/202527.50 USD
11/12/202528.55 USD
11/11/202529.55 USD
11/10/202529.50 USD
11/7/202531.95 USD
11/6/202534.50 USD
11/5/202532.85 USD
11/4/202531.90 USD
11/3/202533.40 USD
10/31/202534.95 USD
10/30/202539.30 USD
10/29/202531.20 USD
10/28/202532.50 USD
10/27/202541.00 USD
10/24/202557.50 USD
10/23/202520.15 USD
10/22/202518.50 USD
10/21/202517.95 USD
10/20/202521.50 USD
10/17/202524.00 USD
10/16/202525.55 USD
10/15/202529.05 USD
10/14/202531.20 USD
10/13/202529.95 USD
10/10/202532.95 USD
10/9/202535.40 USD
10/8/202535.40 USD
10/7/202535.75 USD
10/6/202535.80 USD
10/3/202533.90 USD
10/2/202540.05 USD
10/1/202542.20 USD
9/30/202544.35 USD
9/29/202547.00 USD
9/26/202548.50 USD
9/25/202550.50 USD
9/24/202549.15 USD
9/23/202551.00 USD
9/22/202555.50 USD
9/19/202568.50 USD
9/18/202569.00 USD
9/17/202570.00 USD
9/16/202568.50 USD
9/15/202568.50 USD
9/12/202575.00 USD
9/11/202576.50 USD
9/10/202570.50 USD
9/9/202583.50 USD
9/8/202579.50 USD
9/5/202566.00 USD
9/4/202568.50 USD
9/3/202573.50 USD
9/2/202570.00 USD
8/29/202561.50 USD
8/28/202567.00 USD
8/27/202577.50 USD
8/26/202586.50 USD
8/25/202582.00 USD
8/22/202547.25 USD
8/21/202537.85 USD
8/20/202541.05 USD
8/19/202543.50 USD
8/18/202537.50 USD
8/15/202531.05 USD
8/14/202533.40 USD
8/13/202534.95 USD
8/12/202535.35 USD
8/11/202536.90 USD
8/8/202540.00 USD
Access this data via the Eulerpool API
Get Free API Key

Trxade Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
3.83 M USD
-87,616.00 USD
9,038.00 USD
Jan 1, 2019
7.44 M USD
565,819.00 USD
-409,730.00 USD
Jan 1, 2020
17.12 M USD
-2.51 M USD
-2.57 M USD
Jan 1, 2021
9.89 M USD
-5.29 M USD
-4.11 M USD
Jan 1, 2022
11.45 M USD
-3.59 M USD
-4.31 M USD
Jan 1, 2023
8.27 M USD
-7.26 M USD
-17.84 M USD
Jan 1, 2024 (e)
9.30 M USD
-887,400.00 USD
0.00 USD
Jan 1, 2025 (e)
27.11 M USD
4.77 M USD
13,108.58 USD

Trxade Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 3:43 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
200720082012201320142015201620172018201920202021202220232024e2025e
––––1.004.002.002.003.007.0017.009.0011.008.009.0027.00
–––––300.00-50.00–50.00133.33142.86-47.0622.22-27.2712.50200.00
––––100.0075.00100.00100.00100.0057.1429.4144.4445.4525.0025.0025.00
2.002.002.002.001.003.002.002.003.004.005.004.005.002.002.256.75
–-28.00–-2.00-1.00–––––-2.00-5.00-3.00-7.00–4.00
––––-100.00–––––-11.76-55.56-27.27-87.50–14.81
–-28.00–-2.00-2.00-1.00-2.00–––-2.00-4.00-4.00-17.00––
–––––-50.00100.00––––100.00–325.00––
1.751.751.751.751.751.751.751.751.751.751.751.751.751.751.751.75
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Trxade Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Trxade Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Trxade Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Trxade Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Trxade Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Trxade Group stock margins

The Trxade Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Trxade Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Trxade Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
88.28 %
-2.29 %
0.24 %
Jan 1, 2019
65.50 %
7.61 %
-5.51 %
Jan 1, 2020
33.33 %
-14.64 %
-14.98 %
Jan 1, 2021
47.99 %
-53.51 %
-41.59 %
Jan 1, 2022
47.62 %
-31.40 %
-37.65 %
Jan 1, 2023
31.41 %
-87.80 %
-215.70 %
Jan 1, 2024 (e)
31.41 %
-9.54 %
0.00 %
Jan 1, 2025 (e)
31.41 %
17.59 %
0.05 %

Trxade Group Stock Revenue, EBIT, Earnings per Share

The Trxade Group earnings per share therefore indicates how much revenue Trxade Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024 (e)
5.31 USD
0.00 USD
0.00 USD
Jan 1, 2025 (e)
15.49 USD
0.00 USD
0.01 USD

Trxade Group business model & stock analysis

The Trxade Group Inc is a US-American company that was founded in 2010 and has its headquarters in Tampa, Florida. The company is engaged in the development and operation of an online platform for trading pharmaceuticals and medical products for healthcare facilities and pharmacies. The business model of Trxade is to facilitate and streamline the purchase of pharmaceuticals and medical products for smaller healthcare facilities and pharmacies. To do this, the company operates an online platform that allows customers to order their needed products directly from various suppliers. By using the platform, customers can save time and costs as they no longer have to inquire with various suppliers and place individual orders for products. Instead, they can handle all their orders through the platform and thereby have access to a wider range of products and better prices. Trxade offers its customers various divisions. The main division is the trade of generic pharmaceuticals. Here, the company works closely with various suppliers and manufacturers to offer its customers a wide range of medications. Generic pharmaceuticals are usually cheaper than brand-name medications, allowing the company's customers to save costs. In addition, Trxade also offers other medical products such as vaccines, diagnostics, and medical accessories. Another business area of Trxade is the operation of pharmacies. The company operates several pharmacies under the brand name "Bonum Health," which offer a wide range of medical services. These include, for example, telehealth services, where patients can receive medical advice and assistance from licensed doctors via video call. The pharmacies also offer a wide range of prescription and over-the-counter medications. Trxade has undergone remarkable development in recent years. In 2016, the company went public and in 2019 had a revenue of around 10 million US dollars. Trxade now has over 11,000 registered customers and collaborates with over 450 suppliers and manufacturers. Overall, Trxade is an innovative company focused on simplifying and improving the trade of pharmaceuticals and medical products for smaller healthcare facilities and pharmacies. With its wide range of generic pharmaceuticals, medical accessories, and telehealth services, the company has established a strong position in the market and is expected to continue growing in the coming years.

Trxade Group SWOT Analysis

Strengths

Trxade Group Inc has a strong reputation in the pharmaceutical industry, with years of experience and a solid client base.

The company has developed advanced technology platforms that have allowed them to streamline their operations and improve efficiency.

Trxade Group Inc has a diverse product portfolio, offering a wide range of pharmaceuticals to meet the needs of different customers.

Weaknesses

Trxade Group Inc is heavily reliant on third-party suppliers for their pharmaceutical products, which could be a vulnerability if those suppliers face any issues.

The company operates within a highly regulated industry, which means they must comply with strict rules and regulations, potentially adding complexity and costs to their operations.

Trxade Group Inc may lack brand recognition compared to some of their larger competitors in the market.

Opportunities

The growing demand for affordable and accessible pharmaceuticals presents an opportunity for Trxade Group Inc to expand their customer base.

The company could leverage their advanced technology platforms to offer innovative solutions, such as improving supply chain management or enhancing customer experience.

Trxade Group Inc could explore strategic partnerships or acquisitions to expand their market presence and diversify their product offerings.

Threats

The pharmaceutical industry is highly competitive, with the presence of established players and potential new entrants, posing a threat to Trxade Group Inc's market share.

Changes in government regulations or policies could impact the operations and profitability of Trxade Group Inc.

The ongoing COVID-19 pandemic and its potential long-term effects could disrupt supply chains and affect customer demand for pharmaceutical products.

Trxade Group Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Trxade Group Employees
Details
Date
Trxade Group Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Trxade Group Segments

Trxade Group Revenue by Segment (1/2)

  • Max

Service Revenue
Product Revenue
Details
Date
Service Revenue
Product Revenue
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2023
6.42 M USD
1.85 M USD
Jan 1, 2024
0.00 USD
0.00 USD

Trxade Group Revenue by Segment (2/2)

  • 3 Years

  • 5 Years

  • Max

Integra Pharma, LLC
Trxade, Inc.[Member]
Trxade, Inc.
Trxade Inc
Integra Pharma LLC
Integra Pharma L L C
Community Specialty Pharmacy, LLC
Superlatus
Integra
Unallocated
Other
Other Segments
Details
Date
Integra Pharma, LLC
Trxade, Inc.[Member]
Trxade, Inc.
Trxade Inc
Integra Pharma LLC
Integra Pharma L L C
Community Specialty Pharmacy, LLC
Superlatus
Integra
Unallocated
Other
Other Segments
Jan 1, 2018
0.00 USD
3.41 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
395,418.00 USD
0.00 USD
0.00 USD
0.00 USD
28,538.00 USD
0.00 USD
Jan 1, 2019
1.02 M USD
0.00 USD
4.53 M USD
0.00 USD
0.00 USD
0.00 USD
1.89 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
9.88 M USD
0.00 USD
5.55 M USD
0.00 USD
0.00 USD
0.00 USD
1.65 M USD
0.00 USD
0.00 USD
44,783.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
4.92 M USD
0.00 USD
3.25 M USD
1.65 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
62,016.00 USD
Jan 1, 2022
0.00 USD
5.44 M USD
0.00 USD
0.00 USD
4.75 M USD
0.00 USD
1.18 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
82,910.00 USD
Jan 1, 2023
0.00 USD
6.40 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
487,021.00 USD
1.36 M USD
0.00 USD
0.00 USD
19,204.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
136,643.00 USD
0.00 USD
0.00 USD
0.00 USD

Trxade Group Revenue by Region

  • Max

United States
Details
Date
United States
Jan 1, 2024
136,643.00 USD

Trxade Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Trxade Group historical P/E ratio, EBIT multiple, and P/S ratio

Trxade Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Trxade Group shares outstanding

The number of shares of Trxade Group was 1.75 M in 2025. This indicates how many shares Trxade Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
1.75 M Stocks
Jan 1, 2019
1.75 M Stocks
Jan 1, 2020
1.75 M Stocks
Jan 1, 2021
1.75 M Stocks
Jan 1, 2022
1.75 M Stocks
Jan 1, 2023
1.75 M Stocks
Jan 1, 2024 (e)
1.75 M Stocks
Jan 1, 2025 (e)
1.75 M Stocks

Trxade Group stock splits

In Trxade Group's history, there have been no stock splits.

Trxade Group Dividend History

1 years of dividend payments

YearAnnual DividendYoY ChangePayments
20249.50USD—2×

Current Trxade Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
6.89
Last Price
3.45
Currency
USD
12M Return Potential
99.57 %
LTM Return
0 %

Trxade Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.23USD-0.00USD-2026 Q2
5/13/2024-0.15USD-2.09 MUSD-2024 Q1
3/25/2024-0.15USD-2.39 MUSD-2023 Q4
7/24/2023-0.01USD-3.42 MUSD-2023 Q2
5/8/2023-0.04USD-3.34 MUSD-2023 Q1
3/27/2023-0.07USD-2.68 MUSD-2022 Q4
11/7/2022-0.12USD-3.35 MUSD-2022 Q3
7/25/2022-0.08USD-2.97 MUSD-2022 Q2
5/9/2022-0.12USD-2.24 MUSD-2022 Q1
3/28/2022-0.15USD-2.11 MUSD-2021 Q4

Trxade Group shareholder structure

% Name
12.00547%
Ajjarapu (Surendra K)
Ajjarapu (Surendra K)
10.09605%
Patel Prashant
Patel Prashant
5.42839%
Gundlapalli (Annapurna)
Gundlapalli (Annapurna)
4.98640%
Patel (Nitesh)
Patel (Nitesh)
2.00925%
Fell (Donald G.)
Fell (Donald G.)
0.83129%
The Vanguard Group, Inc.
The Vanguard Group, Inc.

Trxade Group Beneficial Ownership Filings (SEC 13D/G)

Float Shares
-
Shares Outstanding
-
StakeHolderFiling
45.30%
Suren Ajjarapu
Suren Ajjarapu
SEC ↗
39.30%
Prashant Patel
Prashant Patel
SEC ↗
13.00%
Sandhya Ajjarapu
Sandhya Ajjarapu
SEC ↗
9.99%
Steven Boyd
Steven Boyd
SEC ↗
9.99%
Armistice Capital, LLC
Armistice Capital, LLC
SEC ↗
8.57%
Gajan Mahendiran
Gajan Mahendiran
SEC ↗
8.57%
Amudha Mahendiran
Amudha Mahendiran
SEC ↗
8.00%
Rina Patel
Rina Patel
SEC ↗
7.20%
Ajjarapu
Ajjarapu
SEC ↗
5.60%
IDENTIFICATION NOS. OF ABOVE PERSONS (
IDENTIFICATION NOS. OF ABOVE PERSONS (
SEC ↗

Trxade Group Executives and Management Board

6 members · avg. age 59 · 17 % women

SA

Mr. Surendra Ajjarapu (52)

Chairman of the Board, Chief Executive Officer, Secretary · since 2014

430,878.00 USD

Management

PP

Mr. Prashant Patel (49)

President, Interim Chief Financial Officer, Chief Operating Officer, Interim Chief Accounting Officer, Director · since 2014

157,038.00 USD

Board of Directors

DF

Mr. Donald Fell (77)

Independent Director

129,250.00 USD
MP

Mr. Michael Peterson (60)

Independent Director

96,250.00 USD
JN

Mr. Jeff Newell (65)

Independent Director

59,350.00 USD
CB

Ms. Candice Beaumont (49)

Director

–

Trxade Group Supply Chain

Frequently asked questions about Trxade Group

Trxade Group Inc's business model involves operating a web-based healthcare platform, aiming to improve access and affordability of pharmaceutical products to independent pharmacies. The company utilizes technology to connect independent pharmacists with suppliers and manufacturers, creating a transparent marketplace for purchasing and delivering drugs at competitive prices. Trxade Group Inc further offers various services such as prescription and lab testing, consulting, and data analytics to support independent pharmacies in enhancing their operational efficiency and profitability. Through their innovative approach, Trxade Group Inc strives to empower independent pharmacies in the competitive healthcare industry.

Trxade Group Inc is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Trxade Group Inc in the market include pharmaceutical wholesalers and distributors such as McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health Inc. These well-established companies operate on a larger scale compared to Trxade, serving a diverse range of customers including hospitals, retailers, and pharmacies. However, Trxade differentiates itself by focusing on independent pharmacies and providing a comprehensive web-based purchasing platform, offering competitive pricing and efficient inventory management solutions tailored to the needs of its target market.

Trxade Group Inc, founded in 2010, is a leading pharmaceutical supply chain platform in the United States. The company operates Trxade.com, an online marketplace connecting independent pharmacies with suppliers. Trxade's innovative technology and business models aim to revolutionize the healthcare and pharmaceutical industry, promoting fair drug pricing and easier access to medications. With a comprehensive network of pharmacies and suppliers, Trxade Group Inc creates a transparent and efficient marketplace. Its commitment to empowering independent pharmacies has made it a trusted name in the industry. Through continuous advancements and strategic partnerships, Trxade Group Inc continues to shape the future of pharmaceutical commerce.

Trxade Group Inc has achieved several significant milestones in its tenure. The company's key accomplishments include securing a listing on the Nasdaq stock exchange, expanding its reach as a leading web-based pharmaceutical marketplace, and rapidly growing its network of independent pharmacies. Trxade Group Inc has also been recognized for its innovative technologies and solutions, such as its trading platform, which empowers pharmacies to efficiently source medications at competitive prices. This progressive company continues to revolutionize the pharmaceutical industry by connecting independent pharmacies with wholesalers and manufacturers, streamlining operations, and ultimately improving patient access to affordable medications.

Trxade Group Inc is primarily present in the United States.

Trxade Group Inc represents a set of core values and a corporate philosophy that defines its operations. With a focus on transparency, Trxade is dedicated to providing innovative solutions to independent pharmacies, helping them thrive in a competitive industry. The company's commitment to integrity, excellence, and customer-centricity is reflected in its reliable pharmaceutical trading platform and value-added services. Through efficient networking and cost-effective supply chain solutions, Trxade empowers pharmacies to improve patient care while maximizing their profitability. Overall, Trxade Group Inc embodies a customer-first approach, delivering quality products and services to the pharmaceutical industry.

Analysts currently set an average price target of 6.89 USD for the Trxade Group stock (median: 6.89 USD), implying +99.6 % versus the latest price. The consensus is based on 7 analyst ratings.

Trxade Group Analyst Price Targets 2026

7 analysts currently rate the Trxade Group stock: 6 recommend buying, 1 holding and 0 selling.

Trxade Group Analyst Price Targets 2026

Converted at the current exchange rate, the Trxade Group share trades at 2.99 EUR (3.45 USD).

The Trxade Group Inc is a leading company in the healthcare sector, offering innovative solutions to improve efficiency, quality, and transparency in the pharmaceutical supply chain to businesses and individuals. The company operates multiple divisions and provides a variety of products and services to meet customer needs.

The revenue cannot currently be calculated for Trxade Group.

The profit cannot currently be calculated for Trxade Group.

The P/E ratio cannot be calculated for Trxade Group at the moment.

The P/S cannot be calculated for Trxade Group currently.

The Eulerpool Quality Score for Trxade Group is 2/10.

The ISIN of Trxade Group is US89846A2078. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Trxade Group is MEDS. The ticker symbol is used to trade Trxade Group shares on the stock exchange.

Trxade Group paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 9.50 USD are expected. This corresponds to a dividend yield of 275.36 %.

Trxade Group is assigned to the 'Non-cyclical consumption' sector.

To receive the latest dividend of Trxade Group from amounting to 1.5 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Trxade Group are distributed in USD.

All fundamentals and in-depth analysis of Trxade Group

Our stock analysis for Trxade Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trxade Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Trxade Group Stock
Trxade Group Revenue→
Trxade Group Stock
Trxade Group Net Income→
Trxade Group Stock
Trxade Group P/E→
Trxade Group Stock
Trxade Group P/S→
Trxade Group Stock
Trxade Group EBIT→
Trxade Group Stock
Trxade Group Dividend→
Trxade Group Stock
Trxade Group Directors Dealings→
Trxade Group Stock
Trxade Group Stocks→
Trxade Group Stock
Trxade Group Market capitalization→
Trxade Group Stock
Trxade Group Debt→
Trxade Group Stock
Trxade Group Liabilities→
Trxade Group Stock
Trxade Group Equity→
Trxade Group Stock
Trxade Group AAQS→
Trxade Group Stock
Trxade Group Employees→
Trxade Group Stock
Trxade Group ROE→
Trxade Group Stock
Trxade Group ROA→
Trxade Group Stock
Trxade Group ROCE→
Trxade Group Stock
Trxade Group News→
Trxade Group Stock
Trxade Group Analyst Price Targets→

Non-cyclical consumption Stocks

TSTruenorth QuantumTS Trillion CoTropical Canning Thailand PCLTS Wonders HoldingTriveni Engineering and IndustriesTSI Group CoTristar Wellness SolutionsTsingtao Brewery CoTriputra Agro Persada Tbk PTTsit Wing International HoldingsTricom Fruit ProductsAll Stocks A–Z →